Stock Alert: BioNTech Jumps 17% On Positive COVID-19 Vaccine Data

By RTTNews Staff Writer   ✉   | Published:

Shares of BioNTech SE (BNTX) are gaining over 17% on Monday morning after a study revealed that the German biotech company and its partner Pfizer's coronavirus vaccine is more that 90% effective.

BNTX is currently trading at $107.64, up $15.64 or 17.00%, on the Nasdaq.

BNT152b2, the Covid-19 vaccine being developed by Pfizer and BioNTech, was found to be more than 90 percent effective in preventing COVID-19 among patients without prior evidence of infection.

The results were based on the first interim efficacy analysis conducted by an external, independent Data Monitoring Committee or DMC from the vaccine's Phase 3 clinical study.

BNT162b2 was found to be effective against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
FDA Authorizes First Serology Test That Detects COVID-19 Neutralizing Antibodies
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for GenScript USA Inc.'s "cPass SARS-CoV-2 Neutralization Antibody Detection Kit" as the world's first serology test that detects neutralizing antibodies (NAbs) from recent or prior SARS-CoV-2 infection.
Pfizer, BioNTech: COVID-19 Vaccine Candidate More Than 90% Effective
Pharmaceutical giant Pfizer Inc. (PFE) and German biotech firm BioNTech SE (BNTX) said Monday that their coronavirus vaccine candidate, BNT162b2, was found to be more than 90 percent effective in preventing COVID-19 among patients without prior evidence of infection. The results were based on the first interim efficacy analysis conducted from the vaccine's Phase 3 clinical study.
McDonald's Q3 Profit Rises, Tops View
McDonald's Corp. (MCD) reported a profit for the third-quarter that increased about 10 percent from last year, reflecting stronger operating performance in the U.S. due to higher sales-driven restaurant margins, partly offset by sales performance declines in the International Operated Markets and International Developmental Licensed Markets segments as a result of COVID-19.